skip to content

Department of Pharmacology

 

A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from founder Professor Laura Itzhaki’s laboratory...

A spin out of the Department of Pharmacology at the University of Cambridge, PolyProx Therapeutics is based on over a decade of research and intellectual property from founder Professor Laura Itzhaki’s laboratory working closely with co-founders Dr Albert Perez-Riba and Dr Pamela Rowling and with other members of the Itzhaki group.

PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.

Polyproxin™ molecules target disease-causing proteins within tumour cells and trigger pathways to eliminate these proteins, thereby halting further growth of the tumour.  This approach has the potential to address cancer targets that have proven untreatable using current technologies, important in major diseases such as lung, colorectal and pancreatic cancers. The technology behind this approach uses protein scaffolds to link a targeting entity at one end and a degradation trigger at the other, assembled in such a way as to allow access to the tumour cell and recyclable activity.

More details: www.polyprox.com and https://www.cambridgenetwork.co.uk/news/polyprox-therapeutics-3pt4mgbp-seed-financing-cancer-drugs/